Skip to content
Evevident
Original paper
2020NEJMCardiology

EAST-AFNET 4

Early Rhythm-Control Therapy in Patients with Atrial Fibrillation

RCTAtrial fibrillation

On this page

Overview

In recent AF with cardiovascular conditions, early rhythm control reduced major cardiovascular outcomes versus usual care.

Clinical takeaway

EAST-AFNET 4 shifted AF management toward considering rhythm control early after diagnosis in patients with cardiovascular comorbidity, rather than reserving rhythm control only for refractory symptoms.

Key result

The composite of cardiovascular death, stroke, or hospitalization for worsening heart failure or ACS occurred less often with early rhythm control: 3.9 vs 5.0 events per 100 person-years; HR 0.79.

Practice impact

Supports early rhythm-control discussion in newly diagnosed AF with cardiovascular risk or comorbidity.

Evidence

Study design

International, investigator-initiated, randomized, open-label, blinded-outcome-assessment strategy trial.

Enrollment

2,789

Follow-up

Median 5.1 years.

Geography

Europe

Clinical question

In patients with recently diagnosed atrial fibrillation and cardiovascular conditions, does early rhythm-control therapy reduce adverse cardiovascular outcomes compared with usual care?

Population

  • Adults with atrial fibrillation diagnosed within the prior year.
  • Patients had cardiovascular conditions such as age older than 75 years, prior stroke or TIA, heart failure, left ventricular hypertrophy, coronary disease, chronic kidney disease, or other cardiovascular risk factors.

Intervention

Early rhythm-control therapy with antiarrhythmic drugs, cardioversion, or catheter ablation, plus usual evidence-based AF and cardiovascular care.

Comparator

Usual care, initially rate control with rhythm-control therapy used mainly for persistent AF-related symptoms.

Primary outcome

Composite of cardiovascular death, stroke, or hospitalization for worsening heart failure or acute coronary syndrome.

Early rhythm control reduced the primary composite outcome compared with usual care: 3.9 vs 5.0 events per 100 person-years; HR 0.79.

Hazard ratio / 0.79 / CI 96% CI 0.66-0.94 / p=0.005

Key results

  • Primary composite outcome: 3.9 vs 5.0 events per 100 person-years; HR 0.79; 96% CI 0.66-0.94; p=0.005.
  • Mean nights spent in hospital per year were not significantly different between groups.
  • The trial was stopped early for efficacy after a median 5.1 years of follow-up.
  • Benefits were observed in a population with high anticoagulation use and contemporary cardiovascular care.

Harms

  • Serious adverse events related to rhythm-control therapy occurred more often with early rhythm control.
  • Overall primary safety outcomes were similar between the early rhythm-control and usual-care groups.

Clinical Use

When to cite

  • When discussing early rhythm-control strategy soon after AF diagnosis in patients with cardiovascular comorbidity.
  • When contrasting modern early rhythm control with AFFIRM-era rate-control-first practice.

Practice impact

  • Helped move guidelines and clinical practice toward earlier rhythm-control consideration in AF patients with cardiovascular comorbidity.
  • Contrasts with older rate-versus-rhythm trials by studying recently diagnosed AF and allowing contemporary rhythm-control tools including ablation.

Applicability

  • Most applicable to patients with AF diagnosed within 1 year and concomitant cardiovascular conditions.
  • Applies to a strategy of rhythm control, not to a single antiarrhythmic drug or ablation-only approach.

Limitations

  • Open-label strategy trial, although outcomes were adjudicated blinded.
  • Early-stopped trial; absolute benefit was modest over several years.
  • Does not mean every AF patient requires rhythm control regardless of frailty, contraindications, preferences, or procedural risk.

Common misinterpretations

  • Do not cite EAST-AFNET 4 as proof that rhythm control is always superior for long-standing stable AF.
  • Do not stop anticoagulation solely because sinus rhythm is achieved; anticoagulation decisions still depend on thromboembolic risk.

Related evidence

AFFIRM - Earlier TrialCABANA - Context

Citation

Kirchhof P, Camm AJ, Goette A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383(14):1305-1316. doi:10.1056/NEJMoa2019422

Early rhythm-control therapy was associated with a lower risk of adverse cardiovascular outcomes than usual care among patients with early atrial fibrillation and cardiovascular conditions.